136 related articles for article (PubMed ID: 35660381)
41. The metastasis suppressor NDRG1 directly regulates androgen receptor signaling in prostate cancer.
Lim SC; Geleta B; Maleki S; Richardson DR; Kovačević Ž
J Biol Chem; 2021 Dec; 297(6):101414. PubMed ID: 34785213
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
43. Single-cell RNA sequencing reveals an altered gene expression pattern as a result of CRISPR/cas9-mediated deletion of Gene 33/Mig6 and chronic exposure to hexavalent chromium in human lung epithelial cells.
Park S; Zhang X; Li C; Yin C; Li J; Fallon JT; Huang W; Xu D
Toxicol Appl Pharmacol; 2017 Sep; 330():30-39. PubMed ID: 28688920
[TBL] [Abstract][Full Text] [Related]
44. PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling.
Ferreira LB; Palumbo A; de Mello KD; Sternberg C; Caetano MS; de Oliveira FL; Neves AF; Nasciutti LE; Goulart LR; Gimba ER
BMC Cancer; 2012 Nov; 12():507. PubMed ID: 23130941
[TBL] [Abstract][Full Text] [Related]
45. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
[TBL] [Abstract][Full Text] [Related]
46. DUSP22 suppresses prostate cancer proliferation by targeting the EGFR-AR axis.
Lin HP; Ho HM; Chang CW; Yeh SD; Su YW; Tan TH; Lin WJ
FASEB J; 2019 Dec; 33(12):14653-14667. PubMed ID: 31693867
[TBL] [Abstract][Full Text] [Related]
47. A novel androgen-reduced prostate-specific lncRNA, PSLNR, inhibits prostate-cancer progression in part by regulating the p53-dependent pathway.
Wang D; Wan X; Zhang Y; Kong Z; Lu Y; Sun X; Huang Y; Ji C; Li D; Luo J; Gu W; Wang C; Li Y; Xu Y
Prostate; 2019 Sep; 79(12):1362-1377. PubMed ID: 31269242
[TBL] [Abstract][Full Text] [Related]
48. Long-term exposure to low-concentrations of Cr(VI) induce DNA damage and disrupt the transcriptional response to benzo[a]pyrene.
Ovesen JL; Fan Y; Chen J; Medvedovic M; Xia Y; Puga A
Toxicology; 2014 Feb; 316():14-24. PubMed ID: 24374135
[TBL] [Abstract][Full Text] [Related]
49. Lung inflammation, injury, and proliferative response after repetitive particulate hexavalent chromium exposure.
Beaver LM; Stemmy EJ; Schwartz AM; Damsker JM; Constant SL; Ceryak SM; Patierno SR
Environ Health Perspect; 2009 Dec; 117(12):1896-902. PubMed ID: 20049209
[TBL] [Abstract][Full Text] [Related]
50. An AR-Skp2 pathway for proliferation of androgen-dependent prostate-cancer cells.
Wang H; Sun D; Ji P; Mohler J; Zhu L
J Cell Sci; 2008 Aug; 121(Pt 15):2578-87. PubMed ID: 18628304
[TBL] [Abstract][Full Text] [Related]
51. Pharmacological inhibition of androgen receptor expression induces cell death in prostate cancer cells.
Song IS; Jeong YJ; Kim J; Seo KH; Baek NI; Kim Y; Kim CS; Jang SW
Cell Mol Life Sci; 2020 Nov; 77(22):4663-4673. PubMed ID: 31894360
[TBL] [Abstract][Full Text] [Related]
52. Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage.
Li L; Xie H; Liang L; Gao Y; Zhang D; Fang L; Lee SO; Luo J; Chen X; Wang X; Chang LS; Yeh S; Wang Y; He D; Chang C
Carcinogenesis; 2013 Feb; 34(2):257-67. PubMed ID: 23104178
[TBL] [Abstract][Full Text] [Related]
53. Sertad1 promotes prostate cancer progression through binding androgen receptor ligand binding domain.
Hu B; Hu H; Yin M; Sun Z; Chen X; Li Y; Sun Z; Liu C; Li L; Qiu Y
Int J Cancer; 2019 Feb; 144(3):558-568. PubMed ID: 30230528
[TBL] [Abstract][Full Text] [Related]
54. Involvement of the p38 MAP kinase in Cr(VI)-induced growth arrest and apoptosis.
Wakeman TP; Wyczechowska D; Xu B
Mol Cell Biochem; 2005 Nov; 279(1-2):69-73. PubMed ID: 16283515
[TBL] [Abstract][Full Text] [Related]
55. Induction of pro-apoptotic and cell cycle-inhibiting genes in chromium (VI)-treated human lung fibroblasts: lack of effect of ERK.
Ceryak S; Zingariello C; O'Brien T; Patierno SR
Mol Cell Biochem; 2004 Jan; 255(1-2):139-49. PubMed ID: 14971655
[TBL] [Abstract][Full Text] [Related]
56. Lgr4 promotes prostate tumorigenesis through the Jmjd2a/AR signaling pathway.
Zhang J; Li Q; Zhang S; Xu Q; Wang T
Exp Cell Res; 2016 Nov; 349(1):77-84. PubMed ID: 27743893
[TBL] [Abstract][Full Text] [Related]
57. A comparison of the in vitro genotoxicity of tri- and hexavalent chromium.
Blasiak J; Kowalik J
Mutat Res; 2000 Aug; 469(1):135-45. PubMed ID: 10946250
[TBL] [Abstract][Full Text] [Related]
58. Effect of hexavalent chromium-treated sperm on in vitro fertilization and embryo development.
Yoisungnern T; Das J; Choi YJ; Parnpai R; Kim JH
Toxicol Ind Health; 2016 Sep; 32(9):1700-10. PubMed ID: 25903088
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of the effects of androgenic Chinese herbal medicines on androgen receptors and tumor growth in experimental prostate cancer models.
Zhang ZB; Ip SP; Cho WC; Hu Z; Huang YF; Luo DD; Xian YF; Lin ZX
J Ethnopharmacol; 2020 Oct; 260():113058. PubMed ID: 32525068
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival.
Li D; Tian G; Wang J; Zhao LY; Co O; Underill ZC; Mymryk JS; Claessens F; Dehm SM; Daaka Y; Liao D
Prostate; 2018 Nov; 78(15):1140-1156. PubMed ID: 30009471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
